6-K
Silence Therapeutics plc (SLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2021
Commission File Number: 001-39487
Silence Therapeutics plc
(Exact Name of Registrant as Specified in Its Charter)
72 Hammersmith Road
London W14 8TH
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Silence Therapeutics plc held its Annual General Meeting on June 15, 2021. Filed as Exhibit 99.1 to this Report on Form 6-K are the voting results for the resolutions submitted to a vote at the Annual General Meeting.
EXHIBIT INDEX
| Exhibit<br>No. | Description |
|---|---|
| 99.1 | Results of Annual General Meeting |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Silence Therapeutics plc | ||
|---|---|---|
| By: | /s/ Mark Rothera | |
| Name: | Mark Rothera | |
| Title: | President and Chief Executive Officer |
Date: June 15, 2021
sln-ex991_7.htm
Exhibit 99.1
Results of Annual General Meeting
15 June 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its Annual General Meeting held today, 15 June 2021, all resolutions set out in the notice of meeting were duly passed on a poll.
The votes were as follows:
| Resolution<br>*Indicates special resolution | Votes for | % | Votes against | % | Votes total* | % of ISC voted | Votes withheld |
|---|---|---|---|---|---|---|---|
| 1 – Receive and adopt the 2020 UK Annual Report | 36,083,741 | 100.00% | 0 | 0.00% | 36,083,741 | 40.23% | 21,958 |
| 2 – Re-appoint Mark Rothera as a director | 36,030,331 | 99.79% | 74,748 | 0.21% | 36,105,079 | 40.26% | 620 |
| 3 – Re-appoint Dr. Michael Davidson as a director | 36,080,250 | 99.93% | 24,829 | 0.07% | 36,105,079 | 40.26% | 620 |
| 4 – Re-appoint Dr. Giles Campion as a director | 36,042,763 | 99.83% | 62,316 | 0.17% | 36,105,079 | 40.26% | 620 |
| 5 – Approve the directors’ remuneration report | 35,285,210 | 97.73% | 820,064 | 2.27% | 36,105,274 | 40.26% | 425 |
| 6 – Approve the directors’ remuneration policy | 35,240,884 | 97.61% | 864,390 | 2.39% | 36,105,274 | 40.26% | 425 |
| 7 – Re-appoint PricewaterhouseCoopers LLP as auditors of the Company | 27,375,812 | 97.44% | 719,478 | 2.56% | 28,095,290 | 31.33% | 8,010,409 |
| 8 – Authorise the directors to allot shares and grant rights to subscribe for, or convert securities into, shares | 31,771,639 | 99.82% | 57,480 | 0.18% | 31,829,119 | 35.49% | 4,276,580 |
| 9 – Disapply pre-emption rights in connection with an allotment of equity securities for cash* | 29,459,251 | 97.48% | 761,703 | 2.52% | 30,220,954 | 33.70% | 5,884,745 |
The number of the Company’s ordinary shares in issue as at the date of the meeting was 89,685,448 ordinary shares of nominal value 5p each.
*Excludes votes withheld.
A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.
Enquiries:
| Silence Therapeutics plc<br><br><br>Gem Hopkins, Head of IR & Corporate Communications | Tel: +1 (646) 637-3208 |
|---|---|
| Investec Bank plc (Nominated Adviser and Broker)<br><br><br>Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European PR<br><br><br>Consilium Strategic Communications<br><br><br>Mary-Jane Elliott/Chris Welsh/Angela Gray<br><br><br>[email protected] | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.